These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34732240)

  • 1. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
    Lu Z; Chen H; Jiao X; Wang Y; Wu L; Sun H; Li S; Gong J; Li J; Zou J; Yang K; Hu Y; Mao B; Zhang L; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
    Genome Med; 2021 Nov; 13(1):175. PubMed ID: 34732240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.
    Wang Y; Jiao X; Li S; Chen H; Wei X; Liu C; Gong J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Wang Y; Zhuo N; Zou J; Zhang H; Li J; Shen L; Lu Z
    Cancer Biol Med; 2021 Sep; 19(8):1139-49. PubMed ID: 34570439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer.
    Lu Z; Chen H; Li S; Gong J; Li J; Zou J; Wu L; Yu J; Han W; Sun H; Jiao X; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32792358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer.
    Deng S; Gu H; Chen Z; Liu Y; Zhang Q; Chen D; Yi S
    Carcinogenesis; 2024 May; 45(5):351-357. PubMed ID: 38310539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
    Iafolla MAJ; Yang C; Chandran V; Pintilie M; Li Q; Bedard PL; Hansen A; Lheureux S; Spreafico A; Razak AA; Hakgor S; Giesler A; Pugh TJ; Siu LL
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33554038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy.
    Chowell D; Krishna C; Pierini F; Makarov V; Rizvi NA; Kuo F; Morris LGT; Riaz N; Lenz TL; Chan TA
    Nat Med; 2019 Nov; 25(11):1715-1720. PubMed ID: 31700181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
    Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
    Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC-I genotype and tumor mutational burden predict response to immunotherapy.
    Goodman AM; Castro A; Pyke RM; Okamura R; Kato S; Riviere P; Frampton G; Sokol E; Zhang X; Ball ED; Carter H; Kurzrock R
    Genome Med; 2020 May; 12(1):45. PubMed ID: 32430031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
    Naranbhai V; Viard M; Dean M; Groha S; Braun DA; Labaki C; Shukla SA; Yuki Y; Shah P; Chin K; Wind-Rotolo M; Mu XJ; Robbins PB; Gusev A; Choueiri TK; Gulley JL; Carrington M
    Lancet Oncol; 2022 Jan; 23(1):172-184. PubMed ID: 34895481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment.
    Yang Y; Kim E; Kim S
    Genes Genomics; 2022 Apr; 44(4):509-515. PubMed ID: 35107815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
    Cuppens K; Baas P; Geerdens E; Cruys B; Froyen G; Decoster L; Thomeer M; Maes B
    Lung Cancer; 2022 Aug; 170():1-10. PubMed ID: 35689896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
    Chowell D; Morris LGT; Grigg CM; Weber JK; Samstein RM; Makarov V; Kuo F; Kendall SM; Requena D; Riaz N; Greenbaum B; Carroll J; Garon E; Hyman DM; Zehir A; Solit D; Berger M; Zhou R; Rizvi NA; Chan TA
    Science; 2018 Feb; 359(6375):582-587. PubMed ID: 29217585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors.
    Merli P; Crivello P; Strocchio L; Pinto RM; Algeri M; Del Bufalo F; Pagliara D; Becilli M; Carta R; Gaspari S; Galaverna F; Quagliarella F; Boz G; Catanoso ML; Boccieri E; Troiano M; Fleischhauer K; Andreani M; Locatelli F
    Br J Haematol; 2023 Mar; 200(5):622-632. PubMed ID: 36385618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between germ-line HLA and immune-related adverse events.
    Jiang N; Yu Y; Zhang M; Tang Y; Wu D; Wang S; Fang Y; Zhang Y; Meng L; Li Y; Miao H; Ma P; Huang H; Li N
    Front Immunol; 2022; 13():952099. PubMed ID: 36177028
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.